Novo Nordisk, a global healthcare company committed to preventing and treating diabetes, obesity, and other serious chronic diseases, has entered into a new license agreement with Howwe Technologies, an enterprise execution software provider. The partnership, which began in 2017, generated a return on investment of 20 times for Novo Nordisk already in 2018. The license agreement will now be extended until 2025.
Through this partnership, Novo Nordisk will be able to leverage Howwe Technologies’ expertise in enterprise execution to further accelerate its work towards achieving strategic goals, as well as develop cross-functional initiatives to support the development of new products and services that can help patients and their health.
“We are pleased to continue the partnership with Howwe Technologies,” said Niels Abel Bonde, General Manager & VP of Novo Nordisk Scandinavia. “Howwe has become a way of working for our employees and has grown to become an integral part of our success. We believe that this partnership has the potential to be a game-changer for Novo Nordisk as it supports us to maintain a strict focus on our important mission.”
“We’re happy to announce the new worldwide agreement and prolonged collaboration,” said Ulf Arnetz, CEO and Founder of Howwe Technologies. “Howwe enriches how the employees and teams come together to build alignment and achieve better business outcomes for Novo Nordisk. We are confident that Howwe will support Novo Nordisk to achieve results that will have a lasting impact for both the company and its patients.”
Chief Marketing Officer
Howwe Technologies AB (publ) is a Stockholm-based international SaaS company targeting larger organizations. Its SaaS application Howwe® is a proactive tool that helps them to execute their strategies better and faster by visualizing, steering, and measuring the business and strategy acceleration in real-time throughout the entire organization. Howwe helps its customers to create provable and measurable financial results.